FDA Emphasizes Regulatory Flexibility In Biosimilar Reviews
FDA Emphasizes Regulatory Flexibility In Biosimilar Reviews

A study recently published in the BJCP go a long way toward providing a clear example of what regulatory flexibility looks like in the EMA. But where does the FDA, which got a late start with biosimilars, stand in terms of regulatory flexibility today?

  • An Analysis Of The Global Generics Market — Trends & Opportunities
    An Analysis Of The Global Generics Market — Trends & Opportunities

    This article will be part of the CPhI 2016 Annual Report, which will be released during the CPhI Worldwide event in Barcelona (October 4-6, 2016).

  • 4 Questions You Should Be Asking About Biosimilar Adoption
    4 Questions You Should Be Asking About Biosimilar Adoption

    A company needs to be proactive and creative when building the case for its biosimilar to payers. In a recent conference panel, two experts from Express Scripts and Kaiser Permanente share their thoughts on four big questions you might have about biosimilar commercialization and adoption.

  • Are You Overlooking This Critical Component Of Bioprocess Facility Design?
    Are You Overlooking This Critical Component Of Bioprocess Facility Design?

    This article will explore a critical but often overlooked component of bioprocess facility design — HVAC systems — and the realities of HVAC compliance and methods. HVAC is the single continuous and active system that removes the bioburden and particulates introduced by the facilities’ single most contaminating source, humans!

  • Tips For Efficient Comparator Sourcing In Biosimilar Clinical Trials
    Tips For Efficient Comparator Sourcing In Biosimilar Clinical Trials

    There is a lot of pressure for companies to accelerate the clinical development of a biosimilar to make it to market before it becomes overcrowded. One challenge facing companies is comparator sourcing for their Phase 1 and Phase 3 trials. As one expert outlines, there are two different strategies, each presenting drugmakers with different benefits and challenges.

  • Interchangeability: Have Biosimilar Makers Been Set Up To Fail?
    Interchangeability: Have Biosimilar Makers Been Set Up To Fail?

    Last week, the Journal of Managed Care & Specialty Pharmacy (JMCP) published research revealing current pharmacist perceptions on biosimilar naming. A number of media resources have leapt on the findings of this study as indicative of a potential danger the naming system alone could cause. But I feel as though these results speak to a greater issue with interchangeability that is worth examining a little more closely.

  • A Working Introduction To Six Sigma For Pharmaceutical Manufacturers
    A Working Introduction To Six Sigma For Pharmaceutical Manufacturers

    This is the first in a series of articles on Six Sigma that will introduce you to this methodical, rigorous approach to process excellence, and share the author's experiences using the technique in the pharmaceutical industry.

  • Best Practices For Maintaining A Blind In Biosimilar Clinical Trials
    Best Practices For Maintaining A Blind In Biosimilar Clinical Trials

    A more aggressive clinical timeline for biosimilars can get a candidate to market more quickly. But it also becomes more difficult to ensure that clinical trial personnel running biosimilar trials clearly understand their roles and responsibilities, especially when it comes to maintaining a blind. There are several things for sponsors to consider in order to ensure the right people in the trial remain blinded.

  • What Can Biosimilars Learn From The Hepatitis C Payer Battles?
    What Can Biosimilars Learn From The Hepatitis C Payer Battles?

    In December 2014, Express Scripts stunned the pharmaceutical industry when it added AbbVie's Viekira Pak hep C treatment to its 2015 formulary instead of Gilead's Harvoni because of pricing. However, as Steve Miller, CMO of Express Scripts, discussed at the World Biosimilar Congress USA, competitive prices are just the beginning of the commercialization journey.

  • Anti-TNF Biosimilars In Europe: What Matters Beyond Price?
    Anti-TNF Biosimilars In Europe: What Matters Beyond Price?

    The recent introduction in Europe of biosimilar anti-tumor necrosis factor (anti-TNF) drugs has attracted considerable attention. Much of the commentary to date has centered on price, but price tells only part of the story. Structural and perceptual differences have led to considerable heterogeneity in the levels of discounting, access, and uptake throughout and even within European markets.

More Biosimilar editorial...

BIOSIMILAR INSIGHTS

  • From Discovery To Development: GS Expression System For Next-Generation Biologics

    Compared to traditional antibody expression, where routine purification and analytical strategies have been established over the last few years, next-generation biologics have complex designs. If you are first in class or you have a very bespoke up- and downstream process, it also means you will have bigger hurdles to overcome when it comes to regulatory support and filing. At Lonza, these challenges are addressed with the GS™ expression platform.

  • Digging Into The Details: Commonly Asked Questions About Lonza’s XS And GS Expression Systems

    No single strain or vector is capable of being the best expression option for all types of biopharmaceuticals. Experts from Lonza answers questions about the proprietary expression platforms the company has assembled to rapidly generate high-producing cell lines for biological candidates.

  • Three Ways To Maximize Post Marketing Research For Biosimilars

    Proving therapeutic equivalence is an important step in the approval process for a biosimilar. The research needed is time, labor and resource intensive, making it critical to maximize the investment. UBC’s Clinical Development team is supporting a sponsor with a Phase IV study of a gastroenterology biosimilar. This late phase study has yielded three important lessons for biosimilar manufacturers.

  • Perspectives On The Future Of Drug Development And Delivery

    The pharmaceutical industry is moving faster than ever before, continually evolving to meet the changing and growing needs of patients around the world. The industry must continue to adapt in order to meet the increasing demands for new medicines. 

  • A Wake-Up Call For APAC: FDA Requires Electronic Submissions By 2017

    The demand for generic drugs is skyrocketing. According to the US FDA, nearly 8 in 10 prescriptions filled in the United States are for generic drugs. Generic drugs can be considerably less expensive while typically providing the same level of effectiveness as brand name therapeutics. The demand is intensified by initiatives such as the Affordable Care Act that intend to lower the cost of national healthcare by compelling a move toward less expensive generics and biosimilars.

More From Biosimilar...

TRAINING COURSES

Biosimilars: Preparing For Opportunities And Challenges October 11, 2016
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
Medical Device Design Controls 101 – A Practical Crash Course October 12, 2016
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
Electronic Data Integrity in a GxP Environment: Managing the Data Lifecycle for Compliance October 13, 2016
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
22nd Annual Validation Week October 18 - 20, 2016
San Diego, CA
Computerized Systems and Data Integrity – Avoiding The Top Five Regulatory Pitfalls October 24, 2016
1pm-2:30pm EDT, Online Training, PA
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Responding Effectively To FDA Form 483 Observations - Strategies To Ensure Compliance October 25, 2016
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
The Future Of Outsourcing In Clinical Research – Preparing For A Changing Global Landscape October 26, 2016
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
The Impact Of “Brexit” On Clinical Research – An Operational Readiness Primer November 3, 2016
1pm-2:30pm EDT, Online Training
Price:  $299 – Includes Bonus hanouts
Biosimilars North America November 16, 2016
Renaissance Woodbridge Hotel, Iselin, , NJ
More Upcoming Courses
Anna Rose Welch article header

ARCHIVES

ABOUT BIOSIMILAR DEVELOPMENT

Biosimilar Development is dedicated to presenting technical information, thought leadership, and commentary for the biosimilar development and manufacturing community. On this site, users will find exclusive and actionable content on the industry trends and challenges affecting the emerging biosimilars market. Browse our articles, case studies, and white papers on topics related to biosimilar development, manufacturing, quality, distribution, FDA guidance, BPCIA, global markets, government regulations, and intellectual property.

Biosimilar Development is part of the Life Science Connect media group, which strives to facilitate connections and foster collaborations in pharmaceutical development to find ways to get more life-saving and life-improving therapies to market. Connect, Collaborate, Contribute.